MF
Therapeutic Areas
Insmed Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Second Approved Therapy | Respiratory/Rare Disease | Approved |
| ASPEN Study Program | Undisclosed | Phase 3 |
| ARISE Study Program | Undisclosed | Phase 3 |
| PAH Program | Pulmonary Arterial Hypertension | Phase 2b |
| PH-ILD Program | Pulmonary Hypertension Associated with Interstitial Lung Disease | Phase 2a |
Leadership Team at Insmed
WH
William H. Lewis
Chair and Chief Executive Officer
SM
Sara M. Bonstein
Chief Financial Officer
RA
Roger Adsett
Chief Operating Officer
KM
Kevin Mange
Chief Development Officer
ES
Eugene Sullivan
Chief Product Strategy Officer
MS
Michael Smith
Chief Legal Officer
NS
Nicole Schaeffer
Chief People Strategy Officer
AD
Adele Deering
Senior Vice President, Portfolio Strategy & Operational Excellence
CC
Christie Camelio
Chief Compliance Officer
FG
Fenna Gloggner
Director, Insights – EMEA